In recent years, medical innovations have advanced rapidly, especially in the prevention of HIV infection. One of the latest breakthroughs is Injectable PrEP, or Cabotegravir Long-Acting (CAB-LA), a new, convenient, and highly effective option for HIV prevention. Currently, Injectable PrEP has been approved by the World Health Organization (WHO) and the U.S. Food and Drug
